Back to Search
Start Over
MicroRNA and gynecological cancers: Focus on miR-195.
- Source :
-
Pathology, research and practice [Pathol Res Pract] 2023 Sep; Vol. 249, pp. 154784. Date of Electronic Publication: 2023 Aug 24. - Publication Year :
- 2023
-
Abstract
- Different cancer types have been shown to have down-regulated expression levels of miR-195 as an anti-tumor agent. MiR-195 family members can inhibit cancer cell proliferation, angiogenesis, epithelial-mesenchymal transition and metastases, immunosuppression, glycolysis, drug resistance, and cancer stem cell development by targeting the 3'-UTR of the mRNA of different pro-tumor genes. MiR-195 identified as a tumor suppressor miR in a variety of cancers, most notably gynecological malignancies such as cervical, endometrial, and ovarian carcinoma. As a result, restoring miR-195 expression should be regarded as a potential therapy for either prevention or treatment of gynecological cancers. This review will present the most recent data about miR-195-mediated anti-tumor effects in gynecological malignancies, emphasizing its downstream signaling pathways and target genes, as well as prospective treatment techniques.<br />Competing Interests: Declaration of Competing Interest None.<br /> (Copyright © 2023 Elsevier GmbH. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1618-0631
- Volume :
- 249
- Database :
- MEDLINE
- Journal :
- Pathology, research and practice
- Publication Type :
- Academic Journal
- Accession number :
- 37639954
- Full Text :
- https://doi.org/10.1016/j.prp.2023.154784